AstraZeneca is seeing red because a generic drugmaker picked purple as the color for its version of blockbuster heartburn drug Nexium.
AstraZeneca obtained a temporary injunction from a federal judge in Delaware Nov. 6 barring the sale of the generic version of Nexium made by Dr. Reddy’s Laboratories because it was sold in purple capsules—the same color as Nexium. Then, on Nov. 18, Dr. Reddy’s brought its own suit in federal court in Trenton, claiming the Delaware action violates a January 2011 settlement it reached with AstraZeneca, which allowed it to make its own version of Nexium.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
